{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:06Z","timestamp":1740106926672,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00277-022-04938-0","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T19:04:04Z","timestamp":1659121444000},"page":"2545-2547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-4113","authenticated-orcid":false,"given":"Omur Gokmen","family":"Sevindik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmut","family":"Mergen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sena","family":"Mergen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-2822","authenticated-orcid":false,"given":"Yasa Gul","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-7818","authenticated-orcid":false,"given":"Berrin Bal\u0131k","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1855-774X","authenticated-orcid":false,"given":"Istemi","family":"Serin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"4938_CR1","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ (2021) Advances in acute myeloid leukemia. BMJ 375:2026","journal-title":"BMJ"},{"key":"4938_CR2","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/s41375-018-0068-2","volume":"32","author":"AK Eisfeld","year":"2018","unstructured":"Eisfeld AK, Kohlschmidt J, Mr\u00f3zek K et al (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of alliance studies. Leukemia 32:1338\u20131348","journal-title":"Leukemia"},{"key":"4938_CR3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2014.58.0571","volume":"33","author":"F Ostronoff","year":"2015","unstructured":"Ostronoff F, Othus M, Lazenby M et al (2015) Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute\/Medical Research Council report. J Clin Oncol 33:1157\u20131164","journal-title":"J Clin Oncol"},{"key":"4938_CR4","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, L\u00fcbbert M (2021) Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35:1873\u20131889","journal-title":"Leukemia"},{"key":"4938_CR5","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.2217\/fon-2021-0262","volume":"17","author":"TA Othman","year":"2021","unstructured":"Othman TA, Azenkot T, Moskoff BN, Tenold ME, Jonas BA (2021) Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia. Future Oncol 17:2989\u20133005","journal-title":"Future Oncol"},{"key":"4938_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2018-03-785915","volume":"133","author":"V Santini","year":"2019","unstructured":"Santini V (2019) How I treat MDS after hypomethylating agent failure. Blood 133:521\u2013529","journal-title":"Blood"},{"key":"4938_CR7","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1080\/10428194.2020.1808213","volume":"61","author":"TA Othman","year":"2020","unstructured":"Othman TA, Zhang J, Mei M et al (2020) Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. Leuk Lymphoma 61:3532\u20133533","journal-title":"Leuk Lymphoma"},{"key":"4938_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V et al (2022) Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 40:855\u2013865","journal-title":"J Clin Oncol"},{"key":"4938_CR9","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","volume":"5","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Wang SA et al (2021) Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5:1876\u20131883","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04938-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T05:02:36Z","timestamp":1665118956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04938-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4938"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04938-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"2 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from our patient to publish the presentation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}